BIOCRYST PHARMACEUTICALS INC — Director's Dealing 2010

Feb 11, 2010

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK: 0000882796
Period of Report: 2010-02-10

Reporting Person: Mills Mike (Principal Accounting Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2010-02-10	Common Stock	M	4000	$4.34	Acquired	4000	Direct
2010-02-10	Common Stock	M	1146	$3.26	Acquired	5146	Direct
2010-02-10	Common Stock	S	5146	$7.05	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2010-02-10	Emp. Stock Option (Right to Buy)	$4.34	M	4000	Disposed	2015-06-15	Common Stock (4000)	Direct
2010-02-10	Emp. Stock Option (Right to Buy)	$3.26	M	1146	Disposed	2018-03-14	Common Stock (1146)	Direct

Footnotes

F1: The price in column 4 is a weighted average price. The prices actually ranged from $7.04 to $7.07. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares purchased at each price within the range for all transactions reported in this Form 4 utilizing an average weighted price.